Download PDF
Semin Neurol 2011; 31(3): 266-285
DOI: 10.1055/s-0031-1287657
© Thieme Medical Publishers

Infectious Causes of Rapidly Progressive Dementia

Scott M. McGinnis1
  • 1Division of Cognitive and Behavioral Neurology, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
Further Information

Publication History

Publication Date:
30 September 2011 (online)

    Permissions and Reprints

ABSTRACT

Infections represent an uncommon but important to recognize cause of rapidly progressive dementia, as diagnosis and treatment may produce a favorable outcome in selected instances. This article reviews infectious causes of rapidly progressive dementia, including selected viruses, bacteria, fungi, parasites, and prion diseases. Epidemiology, clinical manifestations, imaging characteristics, laboratory diagnosis, and treatment options are discussed.

KEYWORDS

Rapidly progressive dementia - infection

REFERENCES

  • 1 Geschwind M D, Shu H, Haman A, Sejvar J J, Miller B L. Rapidly progressive dementia.  Ann Neurol. 2008;  64 (1) 97-108
    CrossrefPubMedGoogle Scholar
  • 2 Josephs K A, Ahlskog J E, Parisi J E et al.. Rapidly progressive neurodegenerative dementias.  Arch Neurol. 2009;  66 (2) 201-207
    CrossrefPubMedGoogle Scholar
  • 3 Bhaskaran K, Mussini C, Antinori A CASCADE Collaboration et al. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy.  Ann Neurol. 2008;  63 (2) 213-221
    CrossrefPubMedGoogle Scholar
  • 4 Sacktor N, McDermott M P, Marder K et al.. HIV-associated cognitive impairment before and after the advent of combination therapy.  J Neurovirol. 2002;  8 (2) 136-142
    CrossrefPubMedGoogle Scholar
  • 5 Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force.  Neurology. 1991;  41 (6) 778-785
    CrossrefPubMedGoogle Scholar
  • 6 Antinori A, Arendt G, Becker J T et al.. Updated research nosology for HIV-associated neurocognitive disorders.  Neurology. 2007;  69 (18) 1789-1799
    CrossrefPubMedGoogle Scholar
  • 7 Cysique L A, Maruff P, Brew B J. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts.  J Neurovirol. 2004;  10 (6) 350-357
    CrossrefPubMedGoogle Scholar
  • 8 Dunlop O, Bjørklund R, Bruun J N et al.. Early psychomotor slowing predicts the development of HIV dementia and autopsy-verified HIV encephalitis.  Acta Neurol Scand. 2002;  105 (4) 270-275
    CrossrefPubMedGoogle Scholar
  • 9 Stern Y, McDermott M P, Albert S Dana Consortium on the Therapy of HIV-Dementia and Related Cognitive Disorders et al. Factors associated with incident human immunodeficiency virus-dementia.  Arch Neurol. 2001;  58 (3) 473-479
    CrossrefPubMedGoogle Scholar
  • 10 Navia B A, Price R W. The acquired immunodeficiency syndrome dementia complex as the presenting or sole manifestation of human immunodeficiency virus infection.  Arch Neurol. 1987;  44 (1) 65-69
    CrossrefPubMedGoogle Scholar
  • 11 Price R W, Brew B, Sidtis J, Rosenblum M, Scheck A C, Cleary P. The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex.  Science. 1988;  239 (4840) 586-592
    CrossrefPubMedGoogle Scholar
  • 12 McArthur J C, Brew B J, Nath A. Neurological complications of HIV infection.  Lancet Neurol. 2005;  4 (9) 543-555
    CrossrefPubMedGoogle Scholar
  • 13 Broderick D F, Wippold II F J, Clifford D B, Kido D, Wilson B S. White matter lesions and cerebral atrophy on MR images in patients with and without AIDS dementia complex.  AJR Am J Roentgenol. 1993;  161 (1) 177-181
    PubMedGoogle Scholar
  • 14 Olsen W L, Longo F M, Mills C M, Norman D. White matter disease in AIDS: findings at MR imaging.  Radiology. 1988;  169 (2) 445-448
    PubMedGoogle Scholar
  • 15 Thurnher M M, Thurnher S A, Schindler E. CNS involvement in AIDS: spectrum of CT and MR findings.  Eur Radiol. 1997;  7 (7) 1091-1097
    CrossrefPubMedGoogle Scholar
  • 16 Navia B A, Jordan B D, Price R W. The AIDS dementia complex: I. Clinical features.  Ann Neurol. 1986;  19 (6) 517-524
    CrossrefPubMedGoogle Scholar
  • 17 González-Scarano F, Martín-García J. The neuropathogenesis of AIDS.  Nat Rev Immunol. 2005;  5 (1) 69-81
    CrossrefPubMedGoogle Scholar
  • 18 Cysique L A, Vaida F, Letendre S et al.. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy.  Neurology. 2009;  73 (5) 342-348
    CrossrefPubMedGoogle Scholar
  • 19 Marra C M, Zhao Y, Clifford D B AIDS Clinical Trials Group 736 Study Team et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance.  AIDS. 2009;  23 (11) 1359-1366
    CrossrefPubMedGoogle Scholar
  • 20 Sacktor N, Tarwater P M, Skolasky R L Multicenter for AIDS Cohort Study (MACS) et al. CSF antiretroviral drug penetrance and the treatment of HIV-associated psychomotor slowing.  Neurology. 2001;  57 (3) 542-544
    CrossrefPubMedGoogle Scholar
  • 21 Robertson K R, Smurzynski M, Parsons T D et al.. The prevalence and incidence of neurocognitive impairment in the HAART era.  AIDS. 2007;  21 (14) 1915-1921
    CrossrefPubMedGoogle Scholar
  • 22 Tozzi V, Balestra P, Bellagamba R et al.. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors.  J Acquir Immune Defic Syndr. 2007;  45 (2) 174-182
    PubMedGoogle Scholar
  • 23 Padgett B L, Walker D L, ZuRhein G M, Eckroade R J, Dessel B H. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy.  Lancet. 1971;  1 (7712) 1257-1260
    PubMedGoogle Scholar
  • 24 Astrom K E, Mancall E L, Richardson Jr E P. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease.  Brain. 1958;  81 (1) 93-111
    CrossrefPubMedGoogle Scholar
  • 25 Tan C S, Koralnik I J. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.  Lancet Neurol. 2010;  9 (4) 425-437
    CrossrefPubMedGoogle Scholar
  • 26 Koralnik I J, Schellingerhout D, Frosch M P. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 14-2004. A 66-year-old man with progressive neurologic deficits.  N Engl J Med. 2004;  350 (18) 1882-1893
    CrossrefPubMedGoogle Scholar
  • 27 Berger J R, Kaszovitz B, Post M J, Dickinson G. Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. A review of the literature with a report of sixteen cases.  Ann Intern Med. 1987;  107 (1) 78-87
    PubMedGoogle Scholar
  • 28 Engsig F N, Hansen A B, Omland L H et al.. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study.  J Infect Dis. 2009;  199 (1) 77-83
    CrossrefPubMedGoogle Scholar
  • 29 Carson K R, Evens A M, Richey E A et al.. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.  Blood. 2009;  113 (20) 4834-4840
    CrossrefPubMedGoogle Scholar
  • 30 Korman B D, Tyler K L, Korman N J. Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cautionary tale for dermatologists.  Arch Dermatol. 2009;  145 (8) 937-942
    CrossrefPubMedGoogle Scholar
  • 31 Van Assche G, Van Ranst M, Sciot R et al.. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.  N Engl J Med. 2005;  353 (4) 362-368
    CrossrefPubMedGoogle Scholar
  • 32 García-Suárez J, de Miguel D, Krsnik I, Bañas H, Arribas I, Burgaleta C. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies.  Am J Hematol. 2005;  80 (4) 271-281
    CrossrefPubMedGoogle Scholar
  • 33 Gheuens S, Pierone G, Peeters P, Koralnik I J. Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression.  J Neurol Neurosurg Psychiatry. 2010;  81 (3) 247-254
    CrossrefPubMedGoogle Scholar
  • 34 Rockwell D, Ruben F L, Winkelstein A, Mendelow H. Absence of imune deficiencies in a case of progressive multifocal leukoencephalopathy.  Am J Med. 1976;  61 (3) 433-436
    CrossrefPubMedGoogle Scholar
  • 35 Lima M A, Drislane F W, Koralnik I J. Seizures and their outcome in progressive multifocal leukoencephalopathy.  Neurology. 2006;  66 (2) 262-264
    CrossrefPubMedGoogle Scholar
  • 36 Post M J, Yiannoutsos C, Simpson D et al.. Progressive multifocal leukoencephalopathy in AIDS: are there any MR findings useful to patient management and predictive of patient survival? AIDS Clinical Trials Group, 243 Team.  AJNR Am J Neuroradiol. 1999;  20 (10) 1896-1906
    PubMedGoogle Scholar
  • 37 Whiteman M L, Post M J, Berger J R, Tate L G, Bell M D, Limonte L P. Progressive multifocal leukoencephalopathy in 47 HIV-seropositive patients: neuroimaging with clinical and pathologic correlation.  Radiology. 1993;  187 (1) 233-240
    PubMedGoogle Scholar
  • 38 Du Pasquier R A, Koralnik I J. Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial?.  J Neurovirol. 2003;  9 (Suppl 1) 25-31
    PubMedGoogle Scholar
  • 39 Huang D, Cossoy M, Li M et al.. Inflammatory progressive multifocal leukoencephalopathy in human immunodeficiency virus-negative patients.  Ann Neurol. 2007;  62 (1) 34-39
    CrossrefPubMedGoogle Scholar
  • 40 Cinque P, Scarpellini P, Vago L, Linde A, Lazzarin A. Diagnosis of central nervous system complications in HIV-infected patients: cerebrospinal fluid analysis by the polymerase chain reaction.  AIDS. 1997;  11 (1) 1-17
    CrossrefPubMedGoogle Scholar
  • 41 Marzocchetti A, Di Giambenedetto S, Cingolani A, Ammassari A, Cauda R, De Luca A. Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy.  J Clin Microbiol. 2005;  43 (8) 4175-4177
    CrossrefPubMedGoogle Scholar
  • 42 Cinque P, Koralnik I J, Clifford D B. The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: defining a consensus terminology.  J Neurovirol. 2003;  9 (Suppl 1) 88-92
    PubMedGoogle Scholar
  • 43 Kaplan J E, Benson C, Holmes K H, Brooks J T, Pau A, Masur H. Centers for Disease Control and Prevention (CDC) . Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.  MMWR Recomm Rep. 2009;  58 (RR-4) 1-207 quiz CE1-CE4
    PubMedGoogle Scholar
  • 44 Crowder C D, Gyure K A, Drachenberg C B et al.. Successful outcome of progressive multifocal leukoencephalopathy in a renal transplant patient.  Am J Transplant. 2005;  5 (5) 1151-1158
    CrossrefPubMedGoogle Scholar
  • 45 Vulliemoz S, Lurati-Ruiz F, Borruat F X et al.. Favourable outcome of progressive multifocal leucoencephalopathy in two patients with dermatomyositis.  J Neurol Neurosurg Psychiatry. 2006;  77 (9) 1079-1082
    CrossrefPubMedGoogle Scholar
  • 46 Aksamit A J. Treatment of non-AIDS progressive multifocal leukoencephalopathy with cytosine arabinoside.  J Neurovirol. 2001;  7 (4) 386-390
    CrossrefPubMedGoogle Scholar
  • 47 Lindå H, von Heijne A, Major E O et al.. Progressive multifocal leukoencephalopathy after natalizumab monotherapy.  N Engl J Med. 2009;  361 (11) 1081-1087
    CrossrefPubMedGoogle Scholar
  • 48 Wenning W, Haghikia A, Laubenberger J et al.. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.  N Engl J Med. 2009;  361 (11) 1075-1080
    CrossrefPubMedGoogle Scholar
  • 49 Antinori A, Cingolani A, Lorenzini P Italian Registry Investigative Neuro AIDS Study Group et al. Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA).  J Neurovirol. 2003;  9 (Suppl 1) 47-53
    PubMedGoogle Scholar
  • 50 Levitz R E. Herpes simplex encephalitis: a review.  Heart Lung. 1998;  27 (3) 209-212
    CrossrefPubMedGoogle Scholar
  • 51 Whitley R J, Lakeman F. Herpes simplex virus infections of the central nervous system: therapeutic and diagnostic considerations.  Clin Infect Dis. 1995;  20 (2) 414-420
    CrossrefPubMedGoogle Scholar
  • 52 Fisher C M. Hypomanic symptoms caused by herpes simplex encephalitis.  Neurology. 1996;  47 (6) 1374-1378
    CrossrefPubMedGoogle Scholar
  • 53 Hart R P, Kwentus J A, Frazier R B, Hormel T L. Natural history of Klüver-Bucy syndrome after treated herpes encephalitis.  South Med J. 1986;  79 (11) 1376-1378
    CrossrefPubMedGoogle Scholar
  • 54 Domingues R B, Fink M C, Tsanaclis A M et al.. Diagnosis of herpes simplex encephalitis by magnetic resonance imaging and polymerase chain reaction assay of cerebrospinal fluid.  J Neurol Sci. 1998;  157 (2) 148-153
    CrossrefPubMedGoogle Scholar
  • 55 McCabe K, Tyler K, Tanabe J. Diffusion-weighted MRI abnormalities as a clue to the diagnosis of herpes simplex encephalitis.  Neurology. 2003;  61 (7) 1015-1016
    CrossrefPubMedGoogle Scholar
  • 56 Wasay M, Mekan S F, Khelaeni B et al.. Extra temporal involvement in herpes simplex encephalitis.  Eur J Neurol. 2005;  12 (6) 475-479
    CrossrefPubMedGoogle Scholar
  • 57 Misra U K, Kalita J. Neurophysiological studies in herpes simplex encephalitis.  Electromyogr Clin Neurophysiol. 1998;  38 (3) 177-182
    PubMedGoogle Scholar
  • 58 Nahmias A J, Whitley R J, Visintine A N, Takei Y, Alford Jr C A. Herpes simplex virus encephalitis: laboratory evaluations and their diagnostic significance.  J Infect Dis. 1982;  145 (6) 829-836
    CrossrefPubMedGoogle Scholar
  • 59 Aurelius E, Johansson B, Sköldenberg B, Staland A, Forsgren M. Rapid diagnosis of herpes simplex encephalitis by nested polymerase chain reaction assay of cerebrospinal fluid.  Lancet. 1991;  337 (8735) 189-192
    CrossrefPubMedGoogle Scholar
  • 60 DeBiasi R L, Kleinschmidt-DeMasters B K, Weinberg A, Tyler K L. Use of PCR for the diagnosis of herpesvirus infections of the central nervous system.  J Clin Virol. 2002;  25 (Suppl 1) S5-S11
    CrossrefPubMedGoogle Scholar
  • 61 Lakeman F D, Whitley R J. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group . Diagnosis of herpes simplex encephalitis: application of polymerase chain reaction to cerebrospinal fluid from brain-biopsied patients and correlation with disease.  J Infect Dis. 1995;  171 (4) 857-863
    CrossrefPubMedGoogle Scholar
  • 62 Sköldenberg B, Forsgren M, Alestig K et al.. Acyclovir versus vidarabine in herpes simplex encephalitis. Randomised multicentre study in consecutive Swedish patients.  Lancet. 1984;  2 (8405) 707-711
    PubMedGoogle Scholar
  • 63 Whitley R J, Alford C A, Hirsch M S et al.. Vidarabine versus acyclovir therapy in herpes simplex encephalitis.  N Engl J Med. 1986;  314 (3) 144-149
    CrossrefPubMedGoogle Scholar
  • 64 Gordon B, Selnes O A, Hart Jr J, Hanley D F, Whitley R J. Long-term cognitive sequelae of acyclovir-treated herpes simplex encephalitis.  Arch Neurol. 1990;  47 (6) 646-647
    CrossrefPubMedGoogle Scholar
  • 65 Bangen K J, Delano-Wood L, Wierenga C E, Stricker N H, Hesselink J R, Bondi M W. Dementia following herpes zoster encephalitis.  Clin Neuropsychol. 2010;  24 (7) 1193-1203
    CrossrefPubMedGoogle Scholar
  • 66 Valcour V, Haman A, Cornes S Vanderbilt Continuing Medical Education online et al. A case of enteroviral meningoencephalitis presenting as rapidly progressive dementia.  Nat Clin Pract Neurol. 2008;  4 (7) 399-403
    CrossrefPubMedGoogle Scholar
  • 67 Whitley R J, Cobbs C G, Alford Jr C A NIAD Collaborative Antiviral Study Group et al. Diseases that mimic herpes simplex encephalitis. Diagnosis, presentation, and outcome.  JAMA. 1989;  262 (2) 234-239
    CrossrefPubMedGoogle Scholar
  • 68 McNabb S J, Jajosky R A, Hall-Baker P A Centers for Disease Control and Prevention (CDC) et al. Summary of notifiable diseases—United States, 2006.  MMWR Morb Mortal Wkly Rep. 2008;  55 (53) 1-92
    PubMedGoogle Scholar
  • 69 Reimann C A, Hayes E B, DiGuiseppi C et al.. Epidemiology of neuroinvasive arboviral disease in the United States, 1999-2007.  Am J Trop Med Hyg. 2008;  79 (6) 974-979
    PubMedGoogle Scholar
  • 70 Nash D, Mostashari F, Fine A 1999 West Nile Outbreak Response Working Group et al. The outbreak of West Nile virus infection in the New York City area in 1999.  N Engl J Med. 2001;  344 (24) 1807-1814
    CrossrefPubMedGoogle Scholar
  • 71 Saad M, Youssef S, Kirschke D et al.. Acute flaccid paralysis: the spectrum of a newly recognized complication of West Nile virus infection.  J Infect. 2005;  51 (2) 120-127
    CrossrefPubMedGoogle Scholar
  • 72 Fishbein D B, Robinson L E. Rabies.  N Engl J Med. 1993;  329 (22) 1632-1638
    CrossrefPubMedGoogle Scholar
  • 73 Tyler K L. Emerging viral infections of the central nervous system: part 1.  Arch Neurol. 2009;  66 (8) 939-948
    CrossrefPubMedGoogle Scholar
  • 74 Morgello S, Cho E S, Nielsen S, Devinsky O, Petito C K. Cytomegalovirus encephalitis in patients with acquired immunodeficiency syndrome: an autopsy study of 30 cases and a review of the literature.  Hum Pathol. 1987;  18 (3) 289-297
    CrossrefPubMedGoogle Scholar
  • 75 Arribas J R, Storch G A, Clifford D B, Tselis A C. Cytomegalovirus encephalitis.  Ann Intern Med. 1996;  125 (7) 577-587
    PubMedGoogle Scholar
  • 76 Eddleston M, Peacock S, Juniper M, Warrell D A. Severe cytomegalovirus infection in immunocompetent patients.  Clin Infect Dis. 1997;  24 (1) 52-56
    CrossrefPubMedGoogle Scholar
  • 77 McCutchan J A. Cytomegalovirus infections of the nervous system in patients with AIDS.  Clin Infect Dis. 1995;  20 (4) 747-754
    CrossrefPubMedGoogle Scholar
  • 78 Glaser C A, Honarmand S, Anderson L J et al.. Beyond viruses: clinical profiles and etiologies associated with encephalitis.  Clin Infect Dis. 2006;  43 (12) 1565-1577
    CrossrefPubMedGoogle Scholar
  • 79 Deresiewicz R L, Thaler S J, Hsu L, Zamani A A. Clinical and neuroradiographic manifestations of eastern equine encephalitis.  N Engl J Med. 1997;  336 (26) 1867-1874
    CrossrefPubMedGoogle Scholar
  • 80 Lury K M, Castillo M. Eastern equine encephalitis: CT and MRI findings in one case.  Emerg Radiol. 2004;  11 (1) 46-48
    PubMedGoogle Scholar
  • 81 Misra U K, Kalita J. Overview: Japanese encephalitis.  Prog Neurobiol. 2010;  91 (2) 108-120
    CrossrefPubMedGoogle Scholar
  • 82 Petropoulou K A, Gordon S M, Prayson R A, Ruggierri P M. West Nile virus meningoencephalitis: MR imaging findings.  AJNR Am J Neuroradiol. 2005;  26 (8) 1986-1995
    PubMedGoogle Scholar
  • 83 Kupila L, Vuorinen T, Vainionpää R, Hukkanen V, Marttila R J, Kotilainen P. Etiology of aseptic meningitis and encephalitis in an adult population.  Neurology. 2006;  66 (1) 75-80
    CrossrefPubMedGoogle Scholar
  • 84 Huang C, Morse D, Slater B et al.. Multiple-year experience in the diagnosis of viral central nervous system infections with a panel of polymerase chain reaction assays for detection of 11 viruses.  Clin Infect Dis. 2004;  39 (5) 630-635
    CrossrefPubMedGoogle Scholar
  • 85 Whitley R J, Gnann J W. Viral encephalitis: familiar infections and emerging pathogens.  Lancet. 2002;  359 (9305) 507-513
    CrossrefPubMedGoogle Scholar
  • 86 Tunkel A R, Glaser C A, Bloch K C Infectious Diseases Society of America et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America.  Clin Infect Dis. 2008;  47 (3) 303-327
    CrossrefPubMedGoogle Scholar
  • 87 Chong H T, Kamarulzaman A, Tan C T et al.. Treatment of acute Nipah encephalitis with ribavirin.  Ann Neurol. 2001;  49 (6) 810-813
    CrossrefPubMedGoogle Scholar
  • 88 Rahal J J, Anderson J, Rosenberg C, Reagan T, Thompson L L. Effect of interferon-alpha2b therapy on St. Louis viral meningoencephalitis: clinical and laboratory results of a pilot study.  J Infect Dis. 2004;  190 (6) 1084-1087
    CrossrefPubMedGoogle Scholar
  • 89 Bellini W J, Rota J S, Lowe L E et al.. Subacute sclerosing panencephalitis: more cases of this fatal disease are prevented by measles immunization than was previously recognized.  J Infect Dis. 2005;  192 (10) 1686-1693
    CrossrefPubMedGoogle Scholar
  • 90 Dyken P R, Cunningham S C, Ward L C. Changing character of subacute sclerosing panencephalitis in the United States.  Pediatr Neurol. 1989;  5 (6) 339-341
    CrossrefPubMedGoogle Scholar
  • 91 Garg R K. Subacute sclerosing panencephalitis.  J Neurol. 2008;  255 (12) 1861-1871
    CrossrefPubMedGoogle Scholar
  • 92 Gutierrez J, Issacson R S, Koppel B S. Subacute sclerosing panencephalitis: an update.  Dev Med Child Neurol. 2010;  52 (10) 901-907
    CrossrefPubMedGoogle Scholar
  • 93 Miyazaki M, Nishimura M, Toda Y, Saijo T, Mori K, Kuroda Y. Long-term follow-up of a patient with subacute sclerosing panencephalitis successfully treated with intrathecal interferon alpha.  Brain Dev. 2005;  27 (4) 301-303
    CrossrefPubMedGoogle Scholar
  • 94 Oguz K K, Celebi A, Anlar B. MR imaging, diffusion-weighted imaging and MR spectroscopy findings in acute rapidly progressive subacute sclerosing panencephalitis.  Brain Dev. 2007;  29 (5) 306-311
    CrossrefPubMedGoogle Scholar
  • 95 Tuncay R, Akman-Demir G, Gökyigit A et al.. MRI in subacute sclerosing panencephalitis.  Neuroradiology. 1996;  38 (7) 636-640
    CrossrefPubMedGoogle Scholar
  • 96 Praveen-kumar S, Sinha S, Taly A B et al.. Electroencephalographic and imaging profile in a subacute sclerosing panencephalitis (SSPE) cohort: a correlative study.  Clin Neurophysiol. 2007;  118 (9) 1947-1954
    CrossrefPubMedGoogle Scholar
  • 97 Lakshmi V, Malathy Y, Rao R R. Serodiagnosis of subacute sclerosing panencephalitis by enzyme linked immunosorbent assay.  Indian J Pediatr. 1993;  60 (1) 37-41
    CrossrefPubMedGoogle Scholar
  • 98 Risk W S, Haddad F S. The variable natural history of subacute sclerosing panencephalitis: a study of 118 cases from the Middle East.  Arch Neurol. 1979;  36 (10) 610-614
    CrossrefPubMedGoogle Scholar
  • 99 Gascon G G. International Consortium on Subacute Sclerosing Panencephalitis . Randomized treatment study of inosiplex versus combined inosiplex and intraventricular interferon-alpha in subacute sclerosing panencephalitis (SSPE): international multicenter study.  J Child Neurol. 2003;  18 (12) 819-827
    CrossrefPubMedGoogle Scholar
  • 100 Yalaz K, Anlar B, Oktem F et al.. Intraventricular interferon and oral inosiplex in the treatment of subacute sclerosing panencephalitis.  Neurology. 1992;  42 (3 Pt 1) 488-491
    CrossrefPubMedGoogle Scholar
  • 101 Lukehart S A, Hook III E W, Baker-Zander S A, Collier A C, Critchlow C W, Handsfield H H. Invasion of the central nervous system by Treponema pallidum: implications for diagnosis and treatment.  Ann Intern Med. 1988;  109 (11) 855-862
    CrossrefPubMedGoogle Scholar
  • 102 Rolfs R T, Joesoef M R, Hendershot E F The Syphilis and HIV Study Group et al. A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection.  N Engl J Med. 1997;  337 (5) 307-314
    CrossrefPubMedGoogle Scholar
  • 103 Ghanem K G. Review: Neurosyphilis: a historical perspective and review.  CNS Neurosci Ther. 2010;  16 e157-e168
    CrossrefPubMedGoogle Scholar
  • 104 Bash S, Hathout G M, Cohen S. Mesiotemporal T2-weighted hyperintensity: neurosyphilis mimicking herpes encephalitis.  AJNR Am J Neuroradiol. 2001;  22 (2) 314-316
    PubMedGoogle Scholar
  • 105 Marra C M. Neurosyphilis.  Curr Neurol Neurosci Rep. 2004;  4 (6) 435-440
    Google Scholar
  • 106 Timmermans M, Carr J. Neurosyphilis in the modern era.  J Neurol Neurosurg Psychiatry. 2004;  75 (12) 1727-1730
    CrossrefPubMedGoogle Scholar
  • 107 Lee J W, Wilck M, Venna N. Dementia due to neurosyphilis with persistently negative CSF VDRL.  Neurology. 2005;  65 (11) 1838
    CrossrefPubMedGoogle Scholar
  • 108 Johns D R, Tierney M, Felsenstein D. Alteration in the natural history of neurosyphilis by concurrent infection with the human immunodeficiency virus.  N Engl J Med. 1987;  316 (25) 1569-1572
    CrossrefPubMedGoogle Scholar
  • 109 Taylor M M, Aynalem G, Olea L M, He P, Smith L V, Kerndt P R. A consequence of the syphilis epidemic among men who have sex with men (MSM): neurosyphilis in Los Angeles, 2001-2004.  Sex Transm Dis. 2008;  35 (5) 430-434
    PubMedGoogle Scholar
  • 110 Merritt H H, Adams R D, Solomon H C. Neurosyphilis. New York: Oxford University Press; 1946
    Google Scholar
  • 111 Hart G. Syphilis tests in diagnostic and therapeutic decision making.  Ann Intern Med. 1986;  104 (3) 368-376
    PubMedGoogle Scholar
  • 112 Workowski K A, Berman S. Centers for Disease Control and Prevention (CDC) . Sexually transmitted diseases treatment guidelines, 2010.  MMWR Recomm Rep. 2010;  59 (RR-12) 1-110
    PubMedGoogle Scholar
  • 113 Luft B J, Steinman C R, Neimark H C et al.. Invasion of the central nervous system by Borrelia burgdorferi in acute disseminated infection.  JAMA. 1992;  267 (10) 1364-1367
    CrossrefPubMedGoogle Scholar
  • 114 Ackermann R, Rehse-Küpper B, Gollmer E, Schmidt R. Chronic neurologic manifestations of erythema migrans borreliosis.  Ann N Y Acad Sci. 1988;  539 16-23
    CrossrefPubMedGoogle Scholar
  • 115 Halperin J J, Pass H L, Anand A K, Luft B J, Volkman D J, Dattwyler R J. Nervous system abnormalities in Lyme disease.  Ann N Y Acad Sci. 1988;  539 24-34
    CrossrefPubMedGoogle Scholar
  • 116 Logigian E L, Kaplan R F, Steere A C. Chronic neurologic manifestations of Lyme disease.  N Engl J Med. 1990;  323 (21) 1438-1444
    CrossrefPubMedGoogle Scholar
  • 117 Halperin J J, Volkman D J, Wu P. Central nervous system abnormalities in Lyme neuroborreliosis.  Neurology. 1991;  41 (10) 1571-1582
    CrossrefPubMedGoogle Scholar
  • 118 Oksi J, Kalimo H, Marttila R J et al.. Inflammatory brain changes in Lyme borreliosis. A report on three patients and review of literature.  Brain. 1996;  119 (Pt 6) 2143-2154
    CrossrefPubMedGoogle Scholar
  • 119 Steinbach J P, Melms A, Skalej M, Dichgans J. Delayed resolution of white matter changes following therapy of B burgdorferi encephalitis.  Neurology. 2005;  64 (4) 758-759
    CrossrefPubMedGoogle Scholar
  • 120 Centers for Disease Control and Prevention (CDC) . Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease.  MMWR Morb Mortal Wkly Rep. 1995;  44 (31) 590-591
    PubMedGoogle Scholar
  • 121 Wormser G P, Dattwyler R J, Shapiro E D et al.. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America.  Clin Infect Dis. 2006;  43 (9) 1089-1134
    CrossrefPubMedGoogle Scholar
  • 122 Blanc F, Jaulhac B, Fleury M et al.. Relevance of the antibody index to diagnose Lyme neuroborreliosis among seropositive patients.  Neurology. 2007;  69 (10) 953-958
    CrossrefPubMedGoogle Scholar
  • 123 Roos K L, Berger J R. Is the presence of antibodies in CSF sufficient to make a definitive diagnosis of Lyme disease?.  Neurology. 2007;  69 (10) 949-950
    CrossrefPubMedGoogle Scholar
  • 124 Nocton J J, Bloom B J, Rutledge B J et al.. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in cerebrospinal fluid in Lyme neuroborreliosis.  J Infect Dis. 1996;  174 (3) 623-627
    CrossrefPubMedGoogle Scholar
  • 125 Halperin J J. Nervous system Lyme disease.  Infect Dis Clin North Am. 2008;  22 (2) 261-274 vi vi
    CrossrefPubMedGoogle Scholar
  • 126 Clyde Jr W A. Clinical overview of typical Mycoplasma pneumoniae infections.  Clin Infect Dis. 1993;  17 (Suppl 1) S32-S36
    CrossrefPubMedGoogle Scholar
  • 127 Luby J P. Pneumonia caused by Mycoplasma pneumoniae infection.  Clin Chest Med. 1991;  12 (2) 237-244
    PubMedGoogle Scholar
  • 128 Koskiniemi M. CNS manifestations associated with Mycoplasma pneumoniae infections: summary of cases at the University of Helsinki and review.  Clin Infect Dis. 1993;  17 (Suppl 1) S52-S57
    CrossrefPubMedGoogle Scholar
  • 129 Narita M. Pathogenesis of extrapulmonary manifestations of Mycoplasma pneumoniae infection with special reference to pneumonia.  J Infect Chemother. 2010;  16 (3) 162-169
    CrossrefPubMedGoogle Scholar
  • 130 Coelho M, Leite A, Revés A et al.. Mycoplasma pneumoniae causing nervous system lesion and SIADH in the absence of pneumonia.  Clin Neurol Neurosurg. 2004;  106 (2) 129-131
    CrossrefPubMedGoogle Scholar
  • 131 Bitnun A, Ford-Jones E, Blaser S, Richardson S. Mycoplasma pneumoniae ecephalitis.  Semin Pediatr Infect Dis. 2003;  14 (2) 96-107
    CrossrefPubMedGoogle Scholar
  • 132 Daxboeck F. Mycoplasma pneumoniae central nervous system infections.  Curr Opin Neurol. 2006;  19 (4) 374-378
    CrossrefPubMedGoogle Scholar
  • 133 Smith R, Eviatar L. Neurologic manifestations of Mycoplasma pneumoniae infections: diverse spectrum of diseases. A report of six cases and review of the literature.  Clin Pediatr (Phila). 2000;  39 (4) 195-201
    CrossrefPubMedGoogle Scholar
  • 134 Ben-Ami R, Ephros M, Avidor B et al.. Cat-scratch disease in elderly patients.  Clin Infect Dis. 2005;  41 (7) 969-974
    CrossrefPubMedGoogle Scholar
  • 135 Florin T A, Zaoutis T E, Zaoutis L B. Beyond cat scratch disease: widening spectrum of Bartonella henselae infection.  Pediatrics. 2008;  121 (5) e1413-e1425
    CrossrefPubMedGoogle Scholar
  • 136 Arisoy E S, Correa A G, Wagner M L, Kaplan S L. Hepatosplenic cat-scratch disease in children: selected clinical features and treatment.  Clin Infect Dis. 1999;  28 (4) 778-784
    CrossrefPubMedGoogle Scholar
  • 137 Baylor P, Garoufi A, Karpathios T, Lutz J, Mogelof J, Moseley D. Transverse myelitis in 2 patients with Bartonella henselae infection (cat scratch disease).  Clin Infect Dis. 2007;  45 (4) e42-e45
    CrossrefPubMedGoogle Scholar
  • 138 Cunningham E T, Koehler J E. Ocular bartonellosis.  Am J Ophthalmol. 2000;  130 (3) 340-349
    CrossrefPubMedGoogle Scholar
  • 139 Marra C M. Neurologic complications of Bartonella henselae infection.  Curr Opin Neurol. 1995;  8 (3) 164-169
    CrossrefPubMedGoogle Scholar
  • 140 Selby G, Walker G L. Cerebral arteritis in cat-scratch disease.  Neurology. 1979;  29 (10) 1413-1418
    CrossrefPubMedGoogle Scholar
  • 141 Spach D H, Panther L A, Thorning D R, Dunn J E, Plorde J J, Miller R A. Intracerebral bacillary angiomatosis in a patient infected with human immunodeficiency virus.  Ann Intern Med. 1992;  116 (9) 740-742
    PubMedGoogle Scholar
  • 142 Marienfeld C B, Dicapua D B, Sze G K, Goldstein J M. Expressive aphasia as a presentation of encephalitis with Bartonella henselae infection in an immunocompetent adult.  Yale J Biol Med. 2010;  83 (2) 67-71
    PubMedGoogle Scholar
  • 143 Singhal A B, Newstein M C, Budzik R et al.. Diffusion-weighted magnetic resonance imaging abnormalities in Bartonella encephalopathy.  J Neuroimaging. 2003;  13 (1) 79-82
    CrossrefPubMedGoogle Scholar
  • 144 Margileth A M. Recent advances in diagnosis and treatment of cat scratch disease.  Curr Infect Dis Rep. 2000;  2 (2) 141-146
    CrossrefPubMedGoogle Scholar
  • 145 Spach D H, Koehler J E. Bartonella-associated infections.  Infect Dis Clin North Am. 1998;  12 (1) 137-155
    CrossrefPubMedGoogle Scholar
  • 146 Fenollar F, Puéchal X, Raoult D. Whipple's disease.  N Engl J Med. 2007;  356 (1) 55-66
    CrossrefPubMedGoogle Scholar
  • 147 Martinetti M, Biagi F, Badulli C et al.. The HLA alleles DRB1*13 and DQB1*06 are associated to Whipple's disease.  Gastroenterology. 2009;  136 (7) 2289-2294
    CrossrefPubMedGoogle Scholar
  • 148 Marth T, Roux M, von Herbay A, Meuer S C, Feurle G E. Persistent reduction of complement receptor 3 alpha-chain expressing mononuclear blood cells and transient inhibitory serum factors in Whipple's disease.  Clin Immunol Immunopathol. 1994;  72 (2) 217-226
    CrossrefPubMedGoogle Scholar
  • 149 Moos V, Schmidt C, Geelhaar A et al.. Impaired immune functions of monocytes and macrophages in Whipple's disease.  Gastroenterology. 2010;  138 (1) 210-220
    CrossrefPubMedGoogle Scholar
  • 150 Raoult D, Birg M L, La Scola B et al.. Cultivation of the bacillus of Whipple's disease.  N Engl J Med. 2000;  342 (9) 620-625
    CrossrefPubMedGoogle Scholar
  • 151 Durand D V, Lecomte C, Cathébras P, Rousset H, Godeau P. Whipple disease. Clinical review of 52 cases. The SNFMI Research Group on Whipple Disease. Société Nationale Française de Médecine Interne.  Medicine (Baltimore). 1997;  76 (3) 170-184
    CrossrefPubMedGoogle Scholar
  • 152 Panegyres P K, Edis R, Beaman M, Fallon M. Primary Whipple's disease of the brain: characterization of the clinical syndrome and molecular diagnosis.  QJM. 2006;  99 (9) 609-623
    CrossrefPubMedGoogle Scholar
  • 153 Gerard A, Sarrot-Reynauld F, Liozon E et al.. Neurologic presentation of Whipple disease: report of 12 cases and review of the literature.  Medicine (Baltimore). 2002;  81 (6) 443-457
    CrossrefPubMedGoogle Scholar
  • 154 Louis E D, Lynch T, Kaufmann P, Fahn S, Odel J. Diagnostic guidelines in central nervous system Whipple's disease.  Ann Neurol. 1996;  40 (4) 561-568
    CrossrefPubMedGoogle Scholar
  • 155 Matthews B R, Jones L K, Saad D A, Aksamit A J, Josephs K A. Cerebellar ataxia and central nervous system Whipple disease.  Arch Neurol. 2005;  62 (4) 618-620
    CrossrefPubMedGoogle Scholar
  • 156 Schneider T, Moos V, Loddenkemper C, Marth T, Fenollar F, Raoult D. Whipple's disease: new aspects of pathogenesis and treatment.  Lancet Infect Dis. 2008;  8 (3) 179-190
    CrossrefPubMedGoogle Scholar
  • 157 Cohen L, Berthet K, Dauga C, Thivart L, Pierrot-Deseilligny C. Polymerase chain reaction of cerebrospinal fluid to diagnose Whipple's disease.  Lancet. 1996;  347 (8997) 329
    CrossrefPubMedGoogle Scholar
  • 158 von Herbay A, Ditton H J, Schuhmacher F, Maiwald M. Whipple's disease: staging and monitoring by cytology and polymerase chain reaction analysis of cerebrospinal fluid.  Gastroenterology. 1997;  113 (2) 434-441
    CrossrefPubMedGoogle Scholar
  • 159 Elad Y, Nelson P J, Meier D E. Clinical problem-solving. Jumping to the wrong conclusion.  N Engl J Med. 1998;  339 (19) 1382-1387
    CrossrefPubMedGoogle Scholar
  • 160 Heckman G A, Hawkins C, Morris A, Burrows L L, Bergeron C. Rapidly progressive dementia due to Mycobacterium neoaurum meningoencephalitis.  Emerg Infect Dis. 2004;  10 (5) 924-927
    CrossrefPubMedGoogle Scholar
  • 161 Porta-Etessam J, Martínez-Salio A, Berbel A et al.. [Thalamic dementia due to infarct of the left thalamus and genum of the right internal capsule].  Rev Neurol. 2001;  33 (11) 1043-1046
    PubMedGoogle Scholar
  • 162 Bahemuka M, Murungi J H. Tuberculosis of the nervous system. A clinical, radiological and pathological study of 39 consecutive cases in Riyadh, Saudi Arabia.  J Neurol Sci. 1989;  90 (1) 67-76
    CrossrefPubMedGoogle Scholar
  • 163 Berenguer J, Moreno S, Laguna F et al.. Tuberculous meningitis in patients infected with the human immunodeficiency virus.  N Engl J Med. 1992;  326 (10) 668-672
    CrossrefPubMedGoogle Scholar
  • 164 Talati N J, Rouphael N, Kuppalli K, Franco-Paredes C. Spectrum of CNS disease caused by rapidly growing mycobacteria.  Lancet Infect Dis. 2008;  8 (6) 390-398
    CrossrefPubMedGoogle Scholar
  • 165 Kennedy D H, Fallon R J. Tuberculous meningitis.  JAMA. 1979;  241 (3) 264-268
    CrossrefPubMedGoogle Scholar
  • 166 Kent S J, Crowe S M, Yung A, Lucas C R, Mijch A M. Tuberculous meningitis: a 30-year review.  Clin Infect Dis. 1993;  17 (6) 987-994
    CrossrefPubMedGoogle Scholar
  • 167 Streptomycin treatment of tuberculous meningitis.  Lancet. 1948;  1 (6503) 582-596
    PubMedGoogle Scholar
  • 168 Ozateş M, Kemaloglu S, Gürkan F, Ozkan U, Hoşoglu S, Simşek M M. CT of the brain in tuberculous meningitis. A review of 289 patients.  Acta Radiol. 2000;  41 (1) 13-17
    CrossrefPubMedGoogle Scholar
  • 169 Bernaerts A, Vanhoenacker F M, Parizel P M et al.. Tuberculosis of the central nervous system: overview of neuroradiological findings.  Eur Radiol. 2003;  13 (8) 1876-1890
    CrossrefPubMedGoogle Scholar
  • 170 Karandanis D, Shulman J A. Recent survey of infectious meningitis in adults: review of laboratory findings in bacterial, tuberculous, and aseptic meningitis.  South Med J. 1976;  69 (4) 449-457
    CrossrefPubMedGoogle Scholar
  • 171 Thwaites G E, Chau T T, Farrar J J. Improving the bacteriological diagnosis of tuberculous meningitis.  J Clin Microbiol. 2004;  42 (1) 378-379
    CrossrefPubMedGoogle Scholar
  • 172 Noordhoek G T, Kolk A H, Bjune G et al.. Sensitivity and specificity of PCR for detection of Mycobacterium tuberculosis: a blind comparison study among seven laboratories.  J Clin Microbiol. 1994;  32 (2) 277-284
    PubMedGoogle Scholar
  • 173 Bonington A, Strang J I, Klapper P E et al.. Use of Roche AMPLICOR Mycobacterium tuberculosis PCR in early diagnosis of tuberculous meningitis.  J Clin Microbiol. 1998;  36 (5) 1251-1254
    PubMedGoogle Scholar
  • 174 Blumberg H M, Burman W J, Chaisson R E American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis.  Am J Respir Crit Care Med. 2003;  167 (4) 603-662
    CrossrefPubMedGoogle Scholar
  • 175 Joint Tuberculosis Committee of the British Thoracic Society . Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998.  Thorax. 1998;  53 (7) 536-548
    CrossrefPubMedGoogle Scholar
  • 176 Thwaites G E, Lan N T, Dung N H et al.. Effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculous meningitis.  J Infect Dis. 2005;  192 (1) 79-88
    CrossrefPubMedGoogle Scholar
  • 177 Thwaites G E, Nguyen D B, Nguyen H D et al.. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults.  N Engl J Med. 2004;  351 (17) 1741-1751
    CrossrefPubMedGoogle Scholar
  • 178 Schoeman J F, Van Zyl L E, Laubscher J A, Donald P R. Effect of corticosteroids on intracranial pressure, computed tomographic findings, and clinical outcome in young children with tuberculous meningitis.  Pediatrics. 1997;  99 (2) 226-231
    CrossrefPubMedGoogle Scholar
  • 179 Jarvis J N, Harrison T S. HIV-associated cryptococcal meningitis.  AIDS. 2007;  21 (16) 2119-2129
    CrossrefPubMedGoogle Scholar
  • 180 Pappas P G, Perfect J R, Cloud G A et al.. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy.  Clin Infect Dis. 2001;  33 (5) 690-699
    CrossrefPubMedGoogle Scholar
  • 181 Singh N, Lortholary O, Dromer F Cryptococcal Collaborative Transplant Study Group et al. Central nervous system cryptococcosis in solid organ transplant recipients: clinical relevance of abnormal neuroimaging findings.  Transplantation. 2008;  86 (5) 647-651
    PubMedGoogle Scholar
  • 182 Cox G M, Perfect J R. Cryptococcus neoformans var neoformans and gattii and Trichosporon species. In: Edward L A, ed. Topley and Wilson's Microbiology and Microbial Infections. 9th ed. London: Arnold Press; 1997
    Google Scholar
  • 183 Ala T A, Doss R C, Sullivan C J. Reversible dementia: a case of cryptococcal meningitis masquerading as Alzheimer's disease.  J Alzheimers Dis. 2004;  6 (5) 503-508
    PubMedGoogle Scholar
  • 184 Prakash P Y, Sugandhi R P. Neuropsychiatric manifestation of confusional psychosis due to Cryptococcus neoformans var. grubii in an apparently immunocompetent host: a case report.  Cases J. 2009;  2 9084
    CrossrefPubMedGoogle Scholar
  • 185 Sa'adah M A, Araj G F, Diab S M, Nazzal M. Cryptococcal meningitis and confusional psychosis. A case report and literature review.  Trop Geogr Med. 1995;  47 (5) 224-226
    PubMedGoogle Scholar
  • 186 Steiner I, Polacheck I, Melamed E. Dementia and myoclonus in a case of cryptococcal encephalitis.  Arch Neurol. 1984;  41 (2) 216-217
    CrossrefPubMedGoogle Scholar
  • 187 Charlier C, Dromer F, Lévêque C et al.. Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era.  PLoS One. 2008;  3 (4) e1950
    CrossrefPubMedGoogle Scholar
  • 188 Sánchez-Portocarrero J, Pérez-Cecilia E. Intracerebral mass lesions in patients with human immunodeficiency virus infection and cryptococcal meningitis.  Diagn Microbiol Infect Dis. 1997;  29 (3) 193-198
    CrossrefPubMedGoogle Scholar
  • 189 Park M K, Hospenthal D R, Bennett J E. Treatment of hydrocephalus secondary to cryptococcal meningitis by use of shunting.  Clin Infect Dis. 1999;  28 (3) 629-633
    CrossrefPubMedGoogle Scholar
  • 190 Wilcox R A, Thyagarajan D, Kempster P. Two cases of Cryptococcus meningitis presenting as leukoencephalopathy prior to amphotericin therapy.  Eur J Neurol. 2007;  14 (3) 350-352
    CrossrefPubMedGoogle Scholar
  • 191 Darras-Joly C, Chevret S, Wolff M et al.. Cryptococcus neoformans infection in France: epidemiologic features of and early prognostic parameters for 76 patients who were infected with human immunodeficiency virus.  Clin Infect Dis. 1996;  23 (2) 369-376
    CrossrefPubMedGoogle Scholar
  • 192 Shaunak S, Schell W A, Perfect J R. Cryptococcal meningitis with normal cerebrospinal fluid.  J Infect Dis. 1989;  160 (5) 912
    CrossrefPubMedGoogle Scholar
  • 193 Diamond R D, Bennett J E. Prognostic factors in cryptococcal meningitis. A study in 111 cases.  Ann Intern Med. 1974;  80 (2) 176-181
    PubMedGoogle Scholar
  • 194 Dismukes W E, Cloud G, Gallis H A et al.. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks.  N Engl J Med. 1987;  317 (6) 334-341
    CrossrefPubMedGoogle Scholar
  • 195 Tanner D C, Weinstein M P, Fedorciw B, Joho K L, Thorpe J J, Reller L. Comparison of commercial kits for detection of cryptococcal antigen.  J Clin Microbiol. 1994;  32 (7) 1680-1684
    CrossrefPubMedGoogle Scholar
  • 196 Perfect J R, Dismukes W E, Dromer F et al.. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.  Clin Infect Dis. 2010;  50 (3) 291-322
    CrossrefPubMedGoogle Scholar
  • 197 Bach M C, Tally P W, Godofsky E W. Use of cerebrospinal fluid shunts in patients having acquired immunodeficiency syndrome with cryptococcal meningitis and uncontrollable intracranial hypertension.  Neurosurgery. 1997;  41 (6) 1280-1282, discussion 1282–1283
    CrossrefPubMedGoogle Scholar
  • 198 Bach M C, Armstrong R M. Acute toxoplasmic encephalitis in a normal adult.  Arch Neurol. 1983;  40 (9) 596-597
    CrossrefPubMedGoogle Scholar
  • 199 Habek M, Ozretić D, Zarković K, Djaković V, Mubrin Z. Unusual cause of dementia in an immunocompetent host: toxoplasmic encephalitis.  Neurol Sci. 2009;  30 (1) 45-49
    CrossrefPubMedGoogle Scholar
  • 200 Tenter A M, Heckeroth A R, Weiss L M. Toxoplasma gondii: from animals to humans.  Int J Parasitol. 2000;  30 (12-13) 1217-1258
    CrossrefPubMedGoogle Scholar
  • 201 Porter S B, Sande M A. Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome.  N Engl J Med. 1992;  327 (23) 1643-1648
    CrossrefPubMedGoogle Scholar
  • 202 Ciricillo S F, Rosenblum M L. Use of CT and MR imaging to distinguish intracranial lesions and to define the need for biopsy in AIDS patients.  J Neurosurg. 1990;  73 (5) 720-724
    CrossrefPubMedGoogle Scholar
  • 203 Kumar G G, Mahadevan A, Guruprasad A S et al.. Eccentric target sign in cerebral toxoplasmosis: neuropathological correlate to the imaging feature.  J Magn Reson Imaging. 2010;  31 (6) 1469-1472
    CrossrefPubMedGoogle Scholar
  • 204 Masamed R, Meleis A, Lee E W, Hathout G M. Cerebral toxoplasmosis: case review and description of a new imaging sign.  Clin Radiol. 2009;  64 (5) 560-563
    CrossrefPubMedGoogle Scholar
  • 205 Luft B J, Brooks R G, Conley F K, McCabe R E, Remington J S. Toxoplasmic encephalitis in patients with acquired immune deficiency syndrome.  JAMA. 1984;  252 (7) 913-917
    CrossrefPubMedGoogle Scholar
  • 206 Lejon V, Boelaert M, Jannin J, Moore A, Büscher P. The challenge of Trypanosoma brucei gambiense sleeping sickness diagnosis outside Africa.  Lancet Infect Dis. 2003;  3 (12) 804-808
    CrossrefPubMedGoogle Scholar
  • 207 Kennedy P G. Diagnostic and neuropathogenesis issues in human African trypanosomiasis.  Int J Parasitol. 2006;  36 (5) 505-512
    CrossrefPubMedGoogle Scholar
  • 208 Rodgers J. Human African trypanosomiasis, chemotherapy and CNS disease.  J Neuroimmunol. 2009;  211 (1-2) 16-22
    CrossrefPubMedGoogle Scholar
  • 209 Rodgers J. Trypanosomiasis and the brain.  Parasitology. 2010;  137 (14) 1995-2006
    CrossrefPubMedGoogle Scholar
  • 210 Chimelli L, Scaravilli F. Trypanosomiasis.  Brain Pathol. 1997;  7 (1) 599-611
    CrossrefPubMedGoogle Scholar
  • 211 Wéry M, Mulumba P M, Lambert P H, Kazyumba L. Hematologic manifestations, diagnosis, and immunopathology of African trypanosomiasis.  Semin Hematol. 1982;  19 (2) 83-92
    PubMedGoogle Scholar
  • 212 Radwanska M. Emerging trends in the diagnosis of human African Trypanosomiasis.  Parasitology. 2010;  137 (14) 1977-1986
    CrossrefPubMedGoogle Scholar
  • 213 Simarro P P, Ruiz J A, Franco J R, Josenando T. Attitude towards CATT-positive individuals without parasitological confirmation in the African Trypanosomiasis (T.b. gambiense) focus of Quiçama (Angola).  Trop Med Int Health. 1999;  4 (12) 858-861
    CrossrefPubMedGoogle Scholar
  • 214 Truc P, Aerts D, McNamara J J et al.. Direct isolation in vitro of Trypanosoma brucei from man and other animals, and its potential value for the diagnosis of Gambian trypanosomiasis.  Trans R Soc Trop Med Hyg. 1992;  86 (6) 627-629
    CrossrefPubMedGoogle Scholar
  • 215 Lejon V, Sindic C J, Van Antwerpen M P et al.. Human African trypanosomiasis: quantitative and qualitative assessment of intrathecal immune response.  Eur J Neurol. 2003;  10 (6) 711-719
    CrossrefPubMedGoogle Scholar
  • 216 Control and surveillance of African trypanosomiasis. Report of a WHO Expert Committee.  World Health Organ Tech Rep Ser. 1998;  881 I-VI, 1–114
    PubMedGoogle Scholar
  • 217 Braakman H M, van de Molengraft F J, Hubert W W, Boerman D H. Lethal African trypanosomiasis in a traveler: MRI and neuropathology.  Neurology. 2006;  66 (7) 1094-1096
    CrossrefPubMedGoogle Scholar
  • 218 Kager P A, Schipper H G, Stam J, Majoie C B. Magnetic resonance imaging findings in human African trypanosomiasis: a four-year follow-up study in a patient and review of the literature.  Am J Trop Med Hyg. 2009;  80 (6) 947-952
    PubMedGoogle Scholar
  • 219 Kennedy P G. Human African trypanosomiasis of the CNS: current issues and challenges.  J Clin Invest. 2004;  113 (4) 496-504
    Google Scholar
  • 220 Bisser S, N'Siesi F X, Lejon V et al.. Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness.  J Infect Dis. 2007;  195 (3) 322-329
    CrossrefPubMedGoogle Scholar
  • 221 Chappuis F. Melarsoprol-free drug combinations for second-stage Gambian sleeping sickness: the way to go.  Clin Infect Dis. 2007;  45 (11) 1443-1445
    CrossrefPubMedGoogle Scholar
  • 222 Priotto G, Kasparian S, Mutombo W et al.. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial.  Lancet. 2009;  374 (9683) 56-64
    CrossrefPubMedGoogle Scholar
  • 223 Milord F, Pépin J, Loko L, Ethier L, Mpia B. Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness.  Lancet. 1992;  340 (8820) 652-655
    CrossrefPubMedGoogle Scholar
  • 224 Pépin J, Milord F, Khonde A N et al.. Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sickness.  Trans R Soc Trop Med Hyg. 1995;  89 (1) 92-97
    CrossrefPubMedGoogle Scholar
  • 225 Mumba Ngoyi D, Lejon V, Pyana P et al.. How to shorten patient follow-up after treatment for Trypanosoma brucei gambiense sleeping sickness.  J Infect Dis. 2010;  201 (3) 453-463
    CrossrefPubMedGoogle Scholar
  • 226 Cha J H, Furie K, Kay J, Walensky R P, Mullins M E, Hedley-Whyte E T. Case records of the Massachusetts General Hospital. Case 39-2006. A 24-year-old woman with systemic lupus erythematosus, seizures, and right arm weakness.  N Engl J Med. 2006;  355 (25) 2678-2689
    CrossrefPubMedGoogle Scholar
  • 227 Duarte A G, Sattar F, Granwehr B, Aronson J F, Wang Z, Lick S. Disseminated acanthamoebiasis after lung transplantation.  J Heart Lung Transplant. 2006;  25 (2) 237-240
    CrossrefPubMedGoogle Scholar
  • 228 Gonzalez M M, Gould E, Dickinson G et al.. Acquired immunodeficiency syndrome associated with Acanthamoeba infection and other opportunistic organisms.  Arch Pathol Lab Med. 1986;  110 (8) 749-751
    PubMedGoogle Scholar
  • 229 Vernon S E, Acar B C, Pham S M, Fertel D. Acanthamoeba infection in lung transplantation: report of a case and review of the literature.  Transpl Infect Dis. 2005;  7 (3-4) 154-157
    CrossrefPubMedGoogle Scholar
  • 230 Deetz T R, Sawyer M H, Billman G, Schuster F L, Visvesvara G S. Successful treatment of Balamuthia amoebic encephalitis: presentation of 2 cases.  Clin Infect Dis. 2003;  37 (10) 1304-1312
    CrossrefPubMedGoogle Scholar
  • 231 Denney C F, Iragui V J, Uber-Zak L D et al.. Amebic meningoencephalitis caused by Balamuthia mandrillaris: case report and review.  Clin Infect Dis. 1997;  25 (6) 1354-1358
    CrossrefPubMedGoogle Scholar
  • 232 Griesemer D A, Barton L L, Reese C M et al.. Amebic meningoencephalitis caused by Balamuthia mandrillaris.  Pediatr Neurol. 1994;  10 (3) 249-254
    CrossrefPubMedGoogle Scholar
  • 233 Schuster F L, Visvesvara G S. Free-living amoebae as opportunistic and non-opportunistic pathogens of humans and animals.  Int J Parasitol. 2004;  34 (9) 1001-1027
    CrossrefPubMedGoogle Scholar
  • 234 Chappell C L, Wright J A, Coletta M, Newsome A L. Standardized method of measuring acanthamoeba antibodies in sera from healthy human subjects.  Clin Diagn Lab Immunol. 2001;  8 (4) 724-730
    PubMedGoogle Scholar
  • 235 Huang Z H, Ferrante A, Carter R F. Serum antibodies to Balamuthia mandrillaris, a free-living amoeba recently demonstrated to cause granulomatous amoebic encephalitis.  J Infect Dis. 1999;  179 (5) 1305-1308
    CrossrefPubMedGoogle Scholar
  • 236 Schuster F L, Glaser C, Honarmand S, Maguire J H, Visvesvara G S. Balamuthia amebic encephalitis risk, Hispanic Americans.  Emerg Infect Dis. 2004;  10 (8) 1510-1512
    CrossrefPubMedGoogle Scholar
  • 237 Martinez A J. Infection of the central nervous system due to Acanthamoeba.  Rev Infect Dis. 1991;  13 (Suppl 5) S399-S402
    CrossrefPubMedGoogle Scholar
  • 238 Recavarren-Arce S, Velarde C, Gotuzzo E, Cabrera J. Amoeba angeitic lesions of the central nervous system in Balamuthia mandrillaris amoebiasis.  Hum Pathol. 1999;  30 (3) 269-273
    CrossrefPubMedGoogle Scholar
  • 239 Schuster F L, Yagi S, Gavali S et al.. Under the radar: Balamuthia amebic encephalitis.  Clin Infect Dis. 2009;  48 (7) 879-887
    CrossrefPubMedGoogle Scholar
  • 240 Visvesvara G S, Moura H, Schuster F L. Pathogenic and opportunistic free-living amoebae: Acanthamoeba spp., Balamuthia mandrillaris, Naegleria fowleri, and Sappinia diploidea.  FEMS Immunol Med Microbiol. 2007;  50 (1) 1-26
    CrossrefPubMedGoogle Scholar
  • 241 Deol I, Robledo L, Meza A, Visvesvara G S, Andrews R J. Encephalitis due to a free-living amoeba (Balamuthia mandrillaris): case report with literature review.  Surg Neurol. 2000;  53 (6) 611-616
    CrossrefPubMedGoogle Scholar
  • 242 Marciano-Cabral F, Cabral G. Acanthamoeba spp. as agents of disease in humans.  Clin Microbiol Rev. 2003;  16 (2) 273-307
    CrossrefPubMedGoogle Scholar
  • 243 Martinez A J, Visvesvara G S. Free-living, amphizoic and opportunistic amebas.  Brain Pathol. 1997;  7 (1) 583-598
    CrossrefPubMedGoogle Scholar
  • 244 Perez M T, Bush L M. Fatal amebic encephalitis caused by Balamuthia mandrillaris in an immunocompetent host: a clinicopathological review of pathogenic free-living amebae in human hosts.  Ann Diagn Pathol. 2007;  11 (6) 440-447
    CrossrefPubMedGoogle Scholar
  • 245 Healy J F. Balamuthia amebic encephalitis: radiographic and pathologic findings.  AJNR Am J Neuroradiol. 2002;  23 (3) 486-489
    PubMedGoogle Scholar
  • 246 Schuster F L, Honarmand S, Visvesvara G S, Glaser C A. Detection of antibodies against free-living amoebae Balamuthia mandrillaris and Acanthamoeba species in a population of patients with encephalitis.  Clin Infect Dis. 2006;  42 (9) 1260-1265
    CrossrefPubMedGoogle Scholar
  • 247 Centers for Disease Control and Prevention (CDC) . Balamuthia amebic encephalitis—California, 1999-2007.  MMWR Morb Mortal Wkly Rep. 2008;  57 (28) 768-771
    PubMedGoogle Scholar
  • 248 Asiri S, Ogbunude P O, Warhurst D C. In vitro assessment of susceptibility of Acanthamoeba polyphaga to drugs using combined methods of dye-binding assay and uptake of radiolabelled adenosine.  Int J Parasitol. 1994;  24 (7) 975-980
    CrossrefPubMedGoogle Scholar
  • 249 Oliva S, Jantz M, Tiernan R, Cook D L, Judson M A. Successful treatment of widely disseminated acanthamoebiasis.  South Med J. 1999;  92 (1) 55-57
    CrossrefPubMedGoogle Scholar
  • 250 Jung S, Schelper R L, Visvesvara G S, Chang H T. Balamuthia mandrillaris meningoencephalitis in an immunocompetent patient: an unusual clinical course and a favorable outcome.  Arch Pathol Lab Med. 2004;  128 (4) 466-468
    PubMedGoogle Scholar
  • 251 Schuster F L, Guglielmo B J, Visvesvara G S. In-vitro activity of miltefosine and voriconazole on clinical isolates of free-living amebas: Balamuthia mandrillaris, Acanthamoeba spp., and Naegleria fowleri.  J Eukaryot Microbiol. 2006;  53 (2) 121-126
    CrossrefPubMedGoogle Scholar
  • 252 Schuster F L, Visvesvara G S. Opportunistic amoebae: challenges in prophylaxis and treatment.  Drug Resist Updat. 2004;  7 (1) 41-51
    CrossrefPubMedGoogle Scholar
  • 253 Prusiner S B. Prions.  Proc Natl Acad Sci U S A. 1998;  95 (23) 13363-13383
    CrossrefPubMedGoogle Scholar
  • 254 Duffy P, Wolf J, Collins G, DeVoe A G, Streeten B, Cowen D. Letter: Possible person-to-person transmission of Creutzfeldt-Jakob disease.  N Engl J Med. 1974;  290 (12) 692-693
    PubMedGoogle Scholar
  • 255 Ironside J W, Bell J E. Infective dementias.  Panminerva Med. 2007;  49 (4) 209-225
    PubMedGoogle Scholar
  • 256 Brown P, Brandel J P, Preece M, Sato T. Iatrogenic Creutzfeldt-Jakob disease: the waning of an era.  Neurology. 2006;  67 (3) 389-393
    CrossrefPubMedGoogle Scholar
  • 257 Shiga Y, Miyazawa K, Sato S et al.. Diffusion-weighted MRI abnormalities as an early diagnostic marker for Creutzfeldt-Jakob disease.  Neurology. 2004;  63 (3) 443-449
    CrossrefPubMedGoogle Scholar
  • 258 Young G S, Geschwind M D, Fischbein N J et al.. Diffusion-weighted and fluid-attenuated inversion recovery imaging in Creutzfeldt-Jakob disease: high sensitivity and specificity for diagnosis.  AJNR Am J Neuroradiol. 2005;  26 (6) 1551-1562
    PubMedGoogle Scholar
  • 259 Parchi P, Giese A, Capellari S et al.. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects.  Ann Neurol. 1999;  46 (2) 224-233
    CrossrefPubMedGoogle Scholar
  • 260 Collins S J, Sanchez-Juan P, Masters C L et al.. Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease.  Brain. 2006;  129 (Pt 9) 2278-2287
    CrossrefPubMedGoogle Scholar
  • 261 Ironside J W. Variant Creutzfeldt-Jakob disease.  Haemophilia. 2010;  16 (Suppl 5) 175-180
    CrossrefPubMedGoogle Scholar
  • 262 Llewelyn C A, Hewitt P E, Knight R S et al.. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion.  Lancet. 2004;  363 (9407) 417-421
    CrossrefPubMedGoogle Scholar
  • 263 Wilson K, Ricketts M N. Transfusion transmission of vCJD: a crisis avoided?.  Lancet. 2004;  364 (9433) 477-479
    CrossrefPubMedGoogle Scholar
  • 264 Wroe S J, Pal S, Siddique D et al.. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report.  Lancet. 2006;  368 (9552) 2061-2067
    CrossrefPubMedGoogle Scholar
  • 265 Lukic A, Beck J, Joiner S et al.. Heterozygosity at polymorphic codon 219 in variant Creutzfeldt-Jakob disease.  Arch Neurol. 2010;  67 (8) 1021-1023
    CrossrefPubMedGoogle Scholar
  • 266 Spencer M D, Knight R S, Will R G. First hundred cases of variant Creutzfeldt-Jakob disease: retrospective case note review of early psychiatric and neurological features.  BMJ. 2002;  324 (7352) 1479-1482
    CrossrefPubMedGoogle Scholar
  • 267 Zeidler M, Stewart G E, Barraclough C R et al.. New variant Creutzfeldt-Jakob disease: neurological features and diagnostic tests.  Lancet. 1997;  350 (9082) 903-907
    CrossrefPubMedGoogle Scholar
  • 268 Zeidler M, Johnstone E C, Bamber R W et al.. New variant Creutzfeldt-Jakob disease: psychiatric features.  Lancet. 1997;  350 (9082) 908-910
    CrossrefPubMedGoogle Scholar
  • 269 Cordery R J, Alner K, Cipolotti L et al.. The neuropsychology of variant CJD: a comparative study with inherited and sporadic forms of prion disease.  J Neurol Neurosurg Psychiatry. 2005;  76 (3) 330-336
    CrossrefPubMedGoogle Scholar
  • 270 Collie D A, Summers D M, Sellar R J et al.. Diagnosing variant Creutzfeldt-Jakob disease with the pulvinar sign: MR imaging findings in 86 neuropathologically confirmed cases.  AJNR Am J Neuroradiol. 2003;  24 (8) 1560-1569
    PubMedGoogle Scholar
  • 271 Zeidler M, Sellar R J, Collie D A et al.. The pulvinar sign on magnetic resonance imaging in variant Creutzfeldt-Jakob disease.  Lancet. 2000;  355 (9213) 1412-1418
    CrossrefPubMedGoogle Scholar
  • 272 Green A J, Thompson E J, Stewart G E et al.. Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease.  J Neurol Neurosurg Psychiatry. 2001;  70 (6) 744-748
    CrossrefPubMedGoogle Scholar
  • 273 Will R G, Zeidler M, Stewart G E et al.. Diagnosis of new variant Creutzfeldt-Jakob disease.  Ann Neurol. 2000;  47 (5) 575-582
    CrossrefPubMedGoogle Scholar
  • 274 Hill A F, Butterworth R J, Joiner S et al.. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples.  Lancet. 1999;  353 (9148) 183-189
    CrossrefPubMedGoogle Scholar
  • 275 Wadsworth J D, Joiner S, Hill A F et al.. Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay.  Lancet. 2001;  358 (9277) 171-180
    CrossrefPubMedGoogle Scholar
  • 276 Ironside J W, Head M W, Bell J E, McCardle L, Will R G. Laboratory diagnosis of variant Creutzfeldt-Jakob disease.  Histopathology. 2000;  37 (1) 1-9
    CrossrefPubMedGoogle Scholar
  • 277 Will R G, Ironside J W, Zeidler M et al.. A new variant of Creutzfeldt-Jakob disease in the UK.  Lancet. 1996;  347 (9006) 921-925
    CrossrefPubMedGoogle Scholar

Scott M McGinnisM.D. 

Division of Cognitive and Behavioral Neurology, Brigham and Women's Hospital

221 Longwood Avenue, Boston, MA 02115

Email: smmcginnis@partners.org

      >